What’s Going On With EBOS Group (NZSE:EBO)?

Why EBOS Group’s latest earnings and dividend matter now

EBOS Group (NZSE:EBO) has released full year 2026 results alongside a confirmed final dividend. This gives investors fresh information on both recent trading performance and the level of cash returns to shareholders.

The company reported full year sales of A$13,486.68m and net income of A$225.19m for the period to 30 June 2026, with basic earnings per share from continuing operations of A$1.098.

EBOS Group’s latest earnings and dividend update comes after a mixed share price run, with the stock at NZ$21.36 and a 90‑day share price return of 9.43% but a year to date share price return that is down 22.36%. Over the past year the total shareholder return has declined 29.41%, pointing to fading longer term momentum, even as the latest full year result and confirmed final dividend help shape how investors weigh near term growth prospects against risk.

Spot opportunities beyond EBOS Group by reviewing a hand picked 262 high quality undervalued stocks that combine solid fundamentals with valuation support.

Bulls point to EBOS Group’s resilient earnings and maintained dividend, while bears focus on the share price slide over the past year. Which side does the current valuation evidence most support as you evaluate the stock today?

Most Popular Narrative: 29.1% Undervalued

EBOS Group’s most followed narrative places fair value at NZ$30.13, well above the latest close at NZ$21.36. This frames the recent earnings and dividend update in a very different light.

EBOS' major multi-year distribution center renewal program is concluding in FY '26, creating a step-change in logistics capacity, automation, and service efficiency. This is set to significantly lower operating costs and improve margins from FY '27 onwards as capital expenditures normalize and productivity benefits ramp up. (Likely impact: net margins, future earnings growth)

Read the complete narrative.

Want to understand why this fair value sits well above today’s share price? The narrative leans heavily on future margins, capital discipline and scaled revenue assumptions. It is worth examining which specific profit and sales trajectories have been built into that model, and how a single valuation multiple ties them together.

Result: Fair Value of NZ$30.13 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, EBOS Group’s story can change quickly if competitive pressure in pharmacy wholesale keeps margins under strain, or if acquisitions fail to deliver expected benefits.

Find out about the key risks to this EBOS Group narrative.

Another view on EBOS Group’s valuation

The first narrative leans on analyst forecasts and a fair value of NZ$30.13 for EBOS Group, which implies the stock is 29.1% undervalued. On a simpler P/E basis, the picture looks more balanced. EBOS trades around 16.2x earnings, which is close to its 16.1x fair ratio and below the global Healthcare average of 19.8x, and only slightly below peer averages near 16.8x. That narrows the apparent upside and suggests less room for error if growth or margins fall short. Which signal do you treat as the anchor when you weigh the risk of overpaying against the chance of mispricing?

See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

Given the mix of optimism and concern around EBOS Group right now, it makes sense to move quickly and test the story against the facts yourself. You can start with the 4 key rewards and 1 important warning sign.

Looking for more investment ideas beyond EBOS Group?

If you stop at EBOS Group, you could miss other opportunities that fit your style. Use the Simply Wall St Screener to quickly spot ideas that deserve a closer look.

• Target steady income by reviewing a curated set of yield focused companies in the 416 dividend fortresses.
• Pressure test your risk tolerance by scanning for companies with stronger balance sheets in the list of solid balance sheet and fundamentals (428 results).
• Get ahead of the crowd by checking a focused 613 high quality undiscovered gems before attention and pricing potentially shift.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com